Mostrar el registro sencillo del ítem

dc.contributor.authorTorres Sánchez, Alfonso 
dc.contributor.authorRuiz Rodríguez, Alicia 
dc.contributor.authorOrtiz Sandoval, Pilar 
dc.contributor.authorMoreno, María Alejandra
dc.contributor.authorAmpatzoglou, Antonios 
dc.contributor.authorGruszecka-Kosowska, Agnieszka Malgorzata 
dc.contributor.authorMonteoliva Sánchez, Mercedes 
dc.contributor.authorAguilera Gómez, Margarita 
dc.date.accessioned2022-12-05T09:27:43Z
dc.date.available2022-12-05T09:27:43Z
dc.date.issued2022-10-26
dc.identifier.citationTorres-Sánchez, A... [et al.]. Exploring Next Generation Probiotics for Metabolic and Microbiota Dysbiosis Linked to Xenobiotic Exposure: Holistic Approach. Int. J. Mol. Sci. 2022, 23, 12917. [https://doi.org/10.3390/ijms232112917]es_ES
dc.identifier.urihttps://hdl.handle.net/10481/78298
dc.description.abstractVariation of gut microbiota in metabolic diseases seems to be related to dysbiosis induced by exposure to multiple substances called Microbiota Disrupting Chemicals (MDCs), which are present as environmental and dietary contaminants. Some recent studies have focused on elucidating the alterations of gut microbiota taxa and their metabolites as a consequence of xenobiotic exposures to find possible key targets involved in the severity of the host disease triggered. Compilation of data supporting the triad of xenobiotic-microbiota-metabolic diseases would subsequently allow such health misbalances to be prevented or treated by identifying beneficial microbe taxa that could be Next Generation Probiotics (NGPs) with metabolic enzymes for MDC neutralisation and mitigation strategies. In this review, we aim to compile the available information and reports focused on variations of the main gut microbiota taxa in metabolic diseases associated with xenobiotic exposure and related microbial metabolite profiles impacting the host health status. We performed an extensive literature search using SCOPUS, Web of Science, and PubMed databases. The data retrieval and thorough analyses highlight the need for more combined metagenomic and metabolomic studies revealing signatures for xenobiotics and triggered metabolic diseases. Moreover, metabolome and microbiome compositional taxa analyses allow further exploration of how to target beneficial NGP candidates according to their alleged variability abundance and potential therapeutic significance. Furthermore, this holistic approach has identified limitations and the need of future directions to expand and integrate key knowledge to design appropriate clinical and interventional studies with NGPs. Apart from human health, the beneficial microbes and metabolites identified could also be proposed for various applications under One Health, such as probiotics for animals, plants and environmental bioremediation.es_ES
dc.description.sponsorshipFEDER Project Infrastructure IE_2019-198es_ES
dc.description.sponsorshipInstituto de Salud Carlos IIIes_ES
dc.description.sponsorshipEuropean Commission PI20/01278es_ES
dc.description.sponsorshipFIBAO EU-FORA Programme (2020/2021)es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectMicrobiota Disrupting Chemicals (MDCs)es_ES
dc.subjectMicrobiotaes_ES
dc.subjectMetaboliteses_ES
dc.subjectNext Generation Probiotics (NGPs)es_ES
dc.subjectXenobioticses_ES
dc.titleExploring Next Generation Probiotics for Metabolic and Microbiota Dysbiosis Linked to Xenobiotic Exposure: Holistic Approaches_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3390/ijms232112917
dc.type.hasVersionVoRes_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional